氯胺酮
医学
心理信息
加药
安慰剂
梅德林
拟精神病
萧条(经济学)
精神科
临床试验
系统回顾
难治性抑郁症
重性抑郁障碍
重症监护医学
内科学
认知
替代医学
政治学
病理
NMDA受体
宏观经济学
法学
受体
经济
作者
Brooke Short,Joanna Fong,Verònica Gálvez,William Shelker,Colleen Loo
标识
DOI:10.1016/s2215-0366(17)30272-9
摘要
This is the first systematic review of the safety of ketamine in the treatment of depression after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and Cochrane Databases and identified 288 articles, 60 of which met the inclusion criteria. After acute dosing, psychiatric, psychotomimetic, cardiovascular, neurological, and other side-effects were more frequently reported after ketamine treatment than after placebo in patients with depresssion. Our findings suggest a selective reporting bias with limited assessment of long-term use and safety and after repeated dosing, despite these being reported in other patient groups exposed to ketamine (eg, those with chronic pain) and in recreational users. We recommend large-scale clinical trials that include multiple doses of ketamine and long-term follow up to assess the safety of long-term regular use.
科研通智能强力驱动
Strongly Powered by AbleSci AI